Presseaussendungen zu "Magnitude"

84 Aussendungen
vorige Seite Seite 1 von 6 nächste Seite

Magnitude SourceConnect zur Beschleunigung von SAP S

4HANA® für Implementierungen von Central Finance Foundation weltweit

OTS0144
06.12.2019 21:42

Ultragenyx and Kyowa Kirin Announce Topline Phase 3 Study Results Demonstrating Superiority of Crysvita® (burosumab) Treatment to Oral Phosphate and Active Vitamin D in Children with X-Linked Hypophosphatemia (XLH)

Substantial Healing of Rickets Observed in 72% of Patients Treated with Crysvita Compared to 6% of Patients Receiving Conventional Therapy at 40 Weeks

GoverMedia Plus Announces Completion of Initial Public Offering

GoverMedia Plus Canada Corp. (CSE: MPLS) ("GoverMedia" or the "Company") is pleased to announce that, on February 28, 2018, it successfully completed its initial public offering (the "IPO") of 3,546,700 …

OTE0004
01.03.2018 14:56

OncoQuest to Present Oregovomab Phase II Interim Clinical Results for Front Line Treatment of Ovarian Cancer at the American Society of Clinical Oncology (ASCO) Annual Meeting

OncoQuest Inc. ("OncoQuest"), a privately held, biopharmaceutical company focused on the development and commercialization of immunotherapeutic products for the treatment of cancer, today announced the …

OTE0010
24.05.2017 15:32

Bluebee Appoints Two Independent Board Members

Bluebee Holding BV, a leading provider of high performance genomics solutions, today announced the appointment of two new members to its Board of Directors.

OTE0001
08.05.2017 15:46

IXALTIS Announces New Data on the Effects of Litoxetine in Models of Urinary Incontinence at the European Congress of Urology (EAU)

Dr. Philippe Lluel from Urosphere, a company specialized in preclinical pharmacology of urogenital tract, presented on behalf of all investigators two scientific posters at the prestigious congress of the …

OTE0004
27.03.2017 12:40

Resverlogix Provides Groundbreaking Results in Patients with Severe Kidney Impairments

Several Key Proteins That Drive Kidney (Renal) Disease and Dialysis Risk are Downregulated After a Single Dose of Apabetalone

OTE0002
23.01.2017 13:02

TauRx Reports First Phase 3 Results for LMTX®

Promising Read-Out for First-Ever Tau Aggregation Inhibitor to Enter Phase 3 Trials

OTE0003
27.07.2016 14:03
vorige Seite nächste Seite